share_log

Context Therapeutics Highlights 2023 Corporate Priorities And Pipeline Milestones; Co. Announces 'ELONA Breast Cancer Trial Open and Enrolled First Patient'

Context Therapeutics Highlights 2023 Corporate Priorities And Pipeline Milestones; Co. Announces 'ELONA Breast Cancer Trial Open and Enrolled First Patient'

Context Therapeutics 重点介绍了 2023 年企业优先事项和管道宣布 “ELONA乳腺癌试验开始并招收第一位患者”
Benzinga Real-time News ·  2023/01/04 07:34
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today provided 2022 year-end updates and corporate guidance for 2023.
纳斯达克:CNTX)是一家临床阶段的生物制药公司,为实体肿瘤开发新的治疗方法,主要关注女性癌症。该公司今天提供了2022年的最新年终报告和2023年的公司指导。
"I am proud of the substantial progress the Context team made in 2022. We achieved key corporate milestones including nominating CTIM-76 as our Claudin 6 (CLDN6) bispecific antibody clinical candidate and delivering preliminary data in clinical trials of onapristone extended release (ONA-XR), our highly potent and selective progesterone receptor antagonist," said Martin Lehr, CEO of Context. "In 2023, we will continue to advance ONA-XR across the...
Context首席执行官马丁·莱尔说:“我为Context团队在2022年取得的实质性进展感到自豪。我们取得了关键的公司里程碑,...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发